Acyclovir pharmacokinetics in plasmapheresis.
During experimental treatment of human immunodeficiency virus (HIV-1) infection using high doses of acyclovir (ACV) (600 mg IV every 8 h), cyclosporin, and several courses of plasmapheresis (PE) (60 ml/kg), ACV pharmacokinetics in three patients have been measured. The results with or without PE were not significantly different: half-time of elimination 3 vs. 2.3 h, volume of distribution 1.8 vs. 1.14 liter/kg, and total clearance 404 vs. 314 ml/min. The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively. These findings suggest that supplemental doses of ACV are not needed when plasmapheresis is performed.
Chavanet
P Y
PY
Service des Maladies Infectieuses et Tropicales, Hopital du Bocage, Dijon, France.
Bailly
F
F
Mousson
C
C
Waldner-Combernoux
A
A
Lokiec
F
F
Rebibou
J M
JM
Chalopin
J M
JM
Portier
H
H
D000212:Acyclovir / Q000493:pharmacokinetics*; D000328:Adult; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010956:Plasmapheresis
D000212:Acyclovir